DOV Reclaims Rights To Triple Reuptake Inhibitors From Merck
This article was originally published in The Pink Sheet Daily
Executive Summary
DOV says it will seek “broad partnership opportunities” to develop two norepinephrine, serotonin and dopamine reuptake inhibitors for depression.